About Pulmonx Corporation
Pulmonx develops the Zephyr Endobronchial Valve, a bronchoscopic treatment for severe emphysema that reduces hyperinflation and improves lung function.
📍 Location & Offices
📋 Request a Quote
Send your requirements directly to Pulmonx Corporation. Response typically within 48 hours.
Company Info
TypePublic
StockLUNG (NASDAQ)
Founded2000
Employees380
Revenue$68M
HQRedwood City, USA
